← All themesAdvanced Cell & Gene Therapies
Development of therapeutic approaches involving the genetic modification of cells (e.g., T cells, stem cells, macrophages) or the use of viral/non-viral vectors to deliver genetic material for disease treatment.
22,922 US filings from 6,200 companies since 2023 · 2023: 5,425 · 2024: 7,450 · 2025: 7,023 · 2026 YTD: 3,024
Pharmaceutical PreparationsPeptides & Proteins
Top companies
Ranked by filings in this theme since 2023. 2026 is partial.
| # | Company | Since 2023 | 2023 | 2024 | 2025 | 2026 YTD | YoY |
|---|
| 1 | The Regents of the University of California | 579 | 150 | 179 | 174 | 76 | -2.8% |
| 2 | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 385 | 94 | 129 | 110 | 52 | -14.7% |
| 3 | President and Fellows of Harvard College | 290 | 66 | 100 | 94 | 30 | -6.0% |
| 4 | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 236 | 65 | 77 | 69 | 25 | -10.4% |
| 5 | Regeneron Pharmaceuticals, Inc. | 222 | 34 | 79 | 78 | 31 | -1.3% |
| 6 | The Broad Institute, Inc. | 215 | 45 | 61 | 86 | 23 | +41.0% |
| 7 | The Board of Trustees of the Leland Stanford Junior University | 211 | 56 | 65 | 58 | 32 | -10.8% |
| 8 | Memorial Sloan Kettering Cancer Center | 202 | 41 | 70 | 61 | 30 | -12.9% |
| 9 | Immatics Biotechnologies GmbH | 199 | 91 | 64 | 41 | 3 | -35.9% |
| 10 | Board of Regents, The University of Texas System | 186 | 48 | 60 | 58 | 20 | -3.3% |
| 11 | UNIVERSITY OF MASSACHUSETTS | 186 | 49 | 49 | 51 | 37 | +4.1% |
| 12 | City of Hope | 166 | 46 | 47 | 54 | 19 | +14.9% |
| 13 | The General Hospital Corporation | 159 | 34 | 58 | 47 | 20 | -19.0% |
| 14 | The Johns Hopkins University | 150 | 45 | 43 | 44 | 18 | +2.3% |
| 15 | Duke University | 139 | 25 | 60 | 39 | 15 | -35.0% |
| 16 | Novartis AG | 130 | 25 | 50 | 39 | 16 | -22.0% |
| 17 | The United States of America, as represented by the Secretary, Department of Health and Human Services | 128 | 33 | 39 | 37 | 19 | -5.1% |
| 18 | Dana-Farber Cancer Institute, Inc. | 126 | 18 | 43 | 43 | 22 | 0.0% |
| 19 | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 124 | 30 | 35 | 38 | 21 | +8.6% |
| 20 | Genentech, Inc. | 105 | 24 | 36 | 31 | 14 | -13.9% |
| 21 | Regents of the University of Minnesota | 101 | 29 | 32 | 31 | 9 | -3.1% |
| 22 | JANSSEN BIOTECH, INC. | 100 | 16 | 45 | 23 | 16 | -48.9% |
| 23 | Iovance Biotherapeutics, Inc. | 99 | 22 | 36 | 22 | 19 | -38.9% |
| 24 | Mayo Foundation for Medical Education and Research | 99 | 18 | 39 | 29 | 13 | -25.6% |
| 25 | Wisconsin Alumni Research Foundation | 96 | 21 | 39 | 28 | 8 | -28.2% |